Key Highlights
- Tristel Plc (LSE:TSTL) gained 2.41% on 6 October 2026 as investors positioned ahead of full-year results.
- FY26 Revenue rose 10% to £51.1 million, with profit up 14% and cash rising to £16.0 million.
- Tristel ULT and Tristel OPH are cleared for sale in the US, with an FDA submission sought for Tristel ORL.
- New chief executive Chris Lee joined on 1 August 2026.
Tristel Shares Rise on 6 October
Tristel Plc (LSE:TSTL), the global infection prevention company built on proprietary chlorine dioxide chemistry, closed 2.41% higher on Tuesday, 6 October 2026.
London shares closed higher on Tuesday, 6 October 2026, with the FTSE 100 adding 0.4% to 10,541.69 and the FTSE 250 rising 0.4% to 24,215.33. Brent Crude slipped back below $100 a barrel to around $98.37, down from $102.32 a day earlier, after Saudi-backed forces regained control of the Bab el-Mandeb Strait and signs emerged of improving oil flows through the Gulf. Cooler oil prices calmed bond markets, with the US 10-year Treasury Yield easing to 5.27% from 5.33%, while the S&P 500 set a fresh all-time high.
Investor interest in high-margin MedTech companies improved during the session, and Tristel's upcoming full-year results gave buyers a reason to revisit the stock.
Why Tristel Is in Focus
In its July trading update, Tristel confirmed revenue of £51.1 million for the year ended 30 June 2026, up 10% from £46.5 million, alongside profit growth of 14%. Cash balances rose 25% to £16.0 million from £12.8 million, despite continued spending on growth. The board said results were in line with market expectations and consistent with its target of double-digit annual revenue growth.
In the first half, revenue grew 14%, gross Margin held at about 81% and the EBITDA margin reached 28%, above the company's target of at least 25%. Those margins are high for a manufacturer and reflect the value of its patented foam and wipe disinfection systems used for ultrasound probes, endoscopes and other medical devices.
Full-year results are expected in the coming weeks and will include more detail on margins, dividends and the US rollout.
Key Reasons Behind the Share Price Gain
US opportunity. Tristel ULT is FDA-cleared for high-level disinfection of ultrasound probes and is distributed in the US through Parker Laboratories. The company has also received FDA clearance for Tristel OPH, its ophthalmic disinfectant foam, and is seeking approval for Tristel ORL for ENT instruments, already registered in Canada.
Regulatory tailwinds. Updated US guidelines for high-level disinfection of ultrasound probes have increased attention on point-of-care solutions, an area where Tristel's quick-contact-time products are well placed.
Digital revenue. Tristel launched 3T Pro, the first paid tier of its digital compliance platform, offering customisation, reporting and audit-preparation tools, which could add recurring income.
Leadership and Dividends
Chris Lee joined as chief executive on 1 August 2026, succeeding Anna Wasyl, who served as interim chief executive while continuing as finance director after Matt Sassone left for a global role at a large US multinational. Tristel paid an interim Dividend of 5.68p in April 2026 and has a history of progressive Shareholder returns.
What Investors Are Watching
Full-year results will be the near-term focus, especially US revenue growth, margin sustainability, cash generation and the final dividend. The new chief executive's priorities, particularly for North America, will also be closely followed.
Risks include slower US adoption, competition, regulatory timelines and currency movements.
Outlook
Tristel Plc (LSE:TSTL) continues to grow at double-digit rates with high margins and a cash-rich balance sheet, while building a US presence. Tuesday's 2.41% gain reflects anticipation ahead of full-year results and the new leadership's strategy update.






Please wait processing your request...